CNR1 and asphyxia: Further studies are needed to unravel the therapeutic potential of this (and other) treatment(s) for oxidative stress and inflammation after perinatal asphyxia, taking into consideration relevant aspects such as the dose (in this manuscript, only one dose of WIN was tested), the overall impact on the body and long-term outcomes, the temporal schedule of drug administration, and the dual role of some inflammatory mediators such as TNF-α and IL-6 (which can exert either deleterious or beneficial outcomes) or the CBR-dependent and independent effects after CB stimulation.